Dr. Joseph Bresee, chief of the epidemiology prevention branch at the influenza division at the Centers for Disease Control and Prevention (CDC), said for the third consecutive week this season the percent of respiratory specimen testing positive for flu surpassed 10 percent, which is generally a marker to indicate the flu season has begun. “This is the latest start to a flu season in the past 29 years,” said Dr. Bresee.
[More]
Researchers have found that on infecting 41 healthy volunteers with different strains of flu virus, those with higher levels of a specific type of white blood cell were less likely to develop severe illness. Now the team of researchers hopes to mimic the natural resistance shown by some of the volunteers, by creating a vaccine that boosts levels of a particular subset of the 'T-cells'.
[More]
According to World Health Organization researchers there is a rise in Australia in the number of seasonal influenza cases resistant to Tamiflu, the most commonly used antiviral drug. The rise in such cases involving the pandemic 2009 A (H1N1) flu strain, also known as swine flu, took place during Australia's most recent winter: May through August of 2011.
[More]
According to the Centers for Disease Control and Prevention (CDC), three cases of a new flu virus have been confirmed. These originated in pigs but apparently spread from person to person, in three Iowa children.
[More]
Influenza researchers have found that flu strains migrate back and forth between different regions of the world, evolving along the way. This is contrary to the common belief that flu strains from the tropics are the source of global seasonal epidemics.
[More]
A natural lipid in the fluid lining the lungs inhibits influenza infections in both cell cultures and mouse models, according to researchers at National Jewish Health. These findings, combined with previous studies demonstrating effectiveness against respiratory syncytial virus, suggest that the molecule, known as POPG, may have broad antiviral activity.
[More]
SEEK, a leading UK privately-owned drug-discovery group, today announced encouraging results following the successful completion of its Universal Flu Vaccine Phase II challenge study.
[More]
According to a report published online October 25 in The Lancet Infectious Diseases there are gaps in the evidence for the effectiveness of licensed influenza vaccines in the United States. Individuals who are at risk for medical complications or people who are aged 65 years or older are especially affected by the gaps, the researchers write.
[More]
The pivotal pediatric clinical study compared Q/LAIV to two trivalent formulations of MedImmune's licensed seasonal influenza vaccine, FluMist (Influenza Vaccine Live, Intranasal) and met its primary endpoint.
[More]
Sanofi Pasteur, the vaccines division of Sanofi, announced today the results of a new study evaluating the immunogenicity and safety of an investigational quadrivalent inactivated influenza vaccine (QIV) among adults 65 years of age and older.
[More]
Romark Laboratories announced that results of a large Phase 2B-3 US clinical trial of its new flu drug, NT-300 (nitazoxanide), will be presented as an oral late-breaking communication at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) being held in Boston, October 20-23, 2011.
[More]
October marks the beginning of flu season, and once again, health care professionals are exhorting people to get a flu shot. Microbiologist John Tudor, Ph.D., professor of biology at Saint Joseph's University in Philadelphia, agrees that it's time to roll up our sleeves and offer up our arms for the vaccination.
[More]
Britain’s National Health Service (NHS) is urging its staff to take their flu shots amid fresh warnings that low vaccination rates among health professionals could lead to vulnerable patients getting infected and dying. The NHS's employers, health trade unions and the Department of Health have launched a campaign to tackle low immunization rates among frontline staff such as doctors and nurses.
[More]
NanoViricides, Inc. announced today that it has selected a clinical candidate, now designated NV-INF-1, for FDA submission in its highly successful FluCide anti-influenza therapeutics program.
[More]
The Pennsylvania departments of Health and Agriculture today announced three cases of a novel influenza A virus have been identified, and are now linked to an agricultural fair in southwestern Pennsylvania.
[More]
IQuum, Inc. announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market the Liat Influenza A/B Assay and the Liat Analyzer.
[More]
Each year, 200,000 Americans are hospitalized due to flu-related complications.
That number can rise or fall - often dramatically - based on the effectiveness of the selected flu vaccine, said Dr. Jorge Parada, director of infection prevention and control at Loyola University Health System.
[More]
NanoBio Corporation announced today that data from its ferret influenza vaccine study of NB-1008 have been published in the July 2011 issue of Clinical Vaccine Immunology by the American Society of Microbiology.
[More]
The U.S. Food and Drug Administration announced today that it has approved the influenza vaccine formulation for the 2011-2012 vaccine that will be used by the six manufacturers licensed to produce and distribute influenza vaccine for the United States.
[More]
According to an announcement from the Food and Drug Administration (FDA) on Monday, it has approved the new flu vaccine for the season beginning this year. Each year the FDA works with other federal agencies and global health experts to design a vaccine to protect against the three viral strains most likely to cause the flu.
[More]